Corient Private Wealth LLC Has $13.54 Million Stock Holdings in AstraZeneca PLC $AZN

Corient Private Wealth LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 3.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 193,710 shares of the company’s stock after purchasing an additional 6,556 shares during the period. Corient Private Wealth LLC’s holdings in AstraZeneca were worth $13,536,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. NewSquare Capital LLC raised its stake in AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after acquiring an additional 218 shares in the last quarter. Richardson Financial Services Inc. increased its position in AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after purchasing an additional 149 shares in the last quarter. VSM Wealth Advisory LLC acquired a new position in AstraZeneca during the 2nd quarter worth approximately $33,000. FSA Wealth Management LLC lifted its stake in AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after purchasing an additional 376 shares during the last quarter. Finally, Maseco LLP acquired a new stake in AstraZeneca in the second quarter valued at approximately $34,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AZN opened at $90.61 on Friday. The business has a 50-day moving average of $87.46 and a 200-day moving average of $79.65. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. The company has a market capitalization of $281.02 billion, a price-to-earnings ratio of 30.10, a price-to-earnings-growth ratio of 1.66 and a beta of 0.32. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $94.01.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The business had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. During the same period in the prior year, the business posted $2.08 earnings per share. The firm’s revenue was up 12.0% on a year-over-year basis. As a group, equities research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

AZN has been the subject of several research analyst reports. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a report on Wednesday, December 3rd. Cowen reissued a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, HSBC reiterated a “buy” rating and issued a $108.00 price objective on shares of AstraZeneca in a report on Wednesday, December 10th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.